Abscence of specific humoral response in three dogs with clinical leishmaniosis.

BACKGROUND

Canine leishmaniosis, caused by Leishmania infantum, is a vector-borne disease. The immune response in infected dogs determines the clinical outcome, with a strong cell-mediated immune response linked to parasite control and mild clinical signs, while a humoral-dominant response is associated with severe disease. Low antibody levels in clinically asymptomatic dogs with negative molecular and/or parasitological test results may reflect prior exposure or the early stages of Leishmania infection. In contrast, elevated antibody levels are typically correlated with a high parasitic burden and active disease. The detection of dogs with clinical leishmaniosis and null-specific immune response against L. infantum is uncommon. However, this presentation has also been described in human leishmaniasis with the absence of humoral response detected by conventional serological methods.

CASE PRESENTATION

Case 1, a 9-year-old Border Collie, showed splenomegaly and Leishmania amastigotes within splenic macrophages. Case 2, a 10-month-old French Bulldog, had chronic anorexia and malabsorption syndrome with granulomatous splenitis and amastigotes confirmed by immunohistochemistry. Finally, case 3, a 7-year-old cross-breed, presented with cutaneous nodules and nasal ulcerative dermatitis, with Leishmania amastigotes detected histologically and confirmed by immunohistochemistry. All dogs were seronegative by two quantitative serological tests including indirect immunofluorescent test and enzyme-linked immunosorbent assay. The identification of the parasite in the affected organ established a clear cause-and-effect relationship. Consequently, anti-Leishmania treatment was initiated, consisting of allopurinol (10 mg/kg orally twice daily) and meglumine antimoniate (50 mg/kg subcutaneously twice daily for four weeks) in cases 1 and 3. In case 1, a favourable clinical response was noted, with a normal abdominal ultrasound and a negative result by quantitative molecular test from material obtained via ultrasound-guided splenic puncture. In case 3, the administration of meglumine antimoniate resulted in the resolution of dermatological signs. Clinical follow-up and anti-Leishmania treatment could not be performed for case 2.

CONCLUSIONS

These findings highlight the diagnostic challenges in detecting clinical leishmaniosis in seronegative dogs. The absence of a specific humoral response should be considered, emphasizing the importance of using multiple diagnostic methods, including cytology, and histopathology with immunohistochemistry. This case series underscores the need for a comprehensive approach in diagnosing and managing canine leishmaniosis.